Bowlus, Christopher L.

Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis

Hedin, C. R. H., Sado, G., Ndegwa, N., Lytvyak, E., Mason, A., Montano-Loza, A., Gerussi, A., Saffioti, F., Thorburn, D., Nilsson, E., et al. (2020) · Clinical Gastroenterology and Hepatology

Inflammatory Bowel DiseaseLiver Diseases and Immunity

Cited by 52

Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO

Younossi, Z. M., Afendy, A., Stepanova, M., Racila, A., Nader, F., Gomel, R., Safer, R., Lenderking, W. R., Skalicky, A., Kleinman, L., et al. (2018) · Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 48

Clinical Management of Primary Biliary Cholangitis—Strategies and Evolving Trends

Gao, L., Wang, L., Woo, E., He, X., Yang, G., Bowlus, C., Leung, P. S. C., & Gershwin, M. E. (2020) · Clinical Reviews in Allergy & Immunology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 39

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 39

Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis

Pollheimer, M. J., Racedo, S., Mikels-Vigdal, A., Marshall, D., Bowlus, C., Lackner, C., Madl, T., Karlsen, T. H., Hov, J. R., Lyman, S. K., et al. (2018) · Journal of Hepatology

Liver Diseases and ImmunityLiver physiology and pathology

Cited by 38

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Hirschfield, G. M., Bowlus, C. L., Jones, D. E. J., Kremer, A. E., Mayo, M. J., Tanaka, A., Andreone, P., Jia, J., Jin, Q., Macías-Rodríguez, R. U., et al. (2026) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 34

Electronic Medical Alerts Increase Screening for Chronic Hepatitis B: A Randomized, Double-Blind, Controlled Trial

Chak, E., Taefi, A., Li, C.-S., Chen, M. S., Harris, A. M., MacDonald, S., & Bowlus, C. (2018) · Cancer Epidemiology, Biomarkers & Prevention

Electronic Health Records SystemsHepatitis B Virus Studies

Cited by 28

A Fibrosis-Independent hepatic transcriptomic signature identifies drivers of disease progression in primary sclerosing cholangitis

Gindin, Y., Chung, C., Jiang, Z., Zhou, J. Z., Xu, J., Billin, A. N., Myers, R. P., Goodman, Z., Landi, A., Houghton, M., et al. (2021) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 23

Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results

Levy, C., Trivedi, P. J., Kowdley, K. V., Gordon, S. C., Bowlus, C. L., Londoño, M. C., Hirschfield, G. M., Gulamhusein, A., Lawitz, E. J., Vierling, J. M., et al. (2026) · American Journal of Gastroenterology

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 20

Treatment of Primary Biliary Cholangitis

Liu, C.-H., & Bowlus, C. L. (2022) · Clinics in Liver Disease

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 9